Congresso Sio, mepolizumab cambia storia clinica poliposi nasale
(Adnkronos) - Tra i temi al centro del 110° Congresso Nazionale della Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale - Sio, dal tema è “Il Futuro in ascolto”, la rinosinusite cronica con poliposi nasale (CRSwNP) per cui l’anticorpo monoclonale mepolizumab rappresenta una nuova opzione terapeutica. Del farmaco possono beneficiare tutti i pazienti con CRSwNP severa, recidivante, a partire da 150 eosinofili con il vantaggio di un meccanismo d’azione che agisce in modo preciso sull’infiammazione.
Category
🗞
NewsTranscript
00:00The sinusitis with nasal polyposis is a phlogistic pathology, invalidating, chronic, often severe and with a great impact on the patient's quality of life, as it presents a very important symptomatic process.
00:19The eosinophilus is the effective cell and is governed by the interleukin 5, which plays a central role in the genesis of this type of inflammation.
00:29Professor Ignazio Lamantia, CEO of Otorino Laringo Iatria, spoke about it at the 110th Congress of the Italian Society of Otorino Laringo Iatria.
00:42Certainly the eosinophilus is the most important mediator of what we are looking for, it is the biomarker that indicates that we are facing a type 2 inflammation.
00:54Recent researches tell us that the interleukin 5 has a much more important role than the simple activation of the eosinophilus.
01:02We must distinguish between inflammatory eosinophilus and non-inflammatory eosinophilus, but it certainly has an impact on other cells, both hematological and mucosal.
01:15Recent researches have shown that the interleukin 5 plays a central role in the genesis of this type of inflammation.
01:38Mepolizumab is a therapeutic option studied in a context strongly aligned with the guidelines of the International Guidelines,
01:45of which all patients can benefit with chronic rhinosinusitis with severe nasal polyposis and recidivism,
01:52starting from 150 eosinophils with the advantage of an action mechanism that acts precisely on inflammation.
01:59The effectiveness and safety of mepolizumab has been demonstrated by the trials, but in addition to the trials, in the last year several documents have been published in real life.
02:10We know that clinical practice gives outcomes, that is, much more positive responses than the trials, which were already very encouraging.
02:20Recent studies have shown that mepolizumab is effective on all symptoms, not only for very high levels of eosinophils, but also from 150 eosinophils.
02:33Mepolizumab blocks interleukin 5, lowers the level of eosinophils, making them stable over time.
02:41This translates clinically into an improvement in the clinic, in a lower risk of surgery and also a lower risk of systemic steroids.
02:51This is a great advantage for the profile and quality of life of patients.